Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Short Interest Report for October

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 375,939 shares, an increase of 67.5% from the September 30th total of 224,403 shares. Approximately 3.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 168,469 shares, the short-interest ratio is currently 2.2 days.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $0.79 on Monday. Tvardi Therapeutics has a 52 week low of $0.77 and a 52 week high of $5.69. The firm has a market capitalization of $10.58 million, a price-to-earnings ratio of -0.28 and a beta of 0.37. The company has a 50 day moving average price of $1.38 and a 200 day moving average price of $2.77.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Equities analysts forecast that Tvardi Therapeutics will post -2.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. Chardan Capital started coverage on Tvardi Therapeutics in a research report on Tuesday, October 20th. They set a “buy” rating for the company. Finally, Wall Street Zen lowered Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.40.

Hedge Funds Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Tvardi Therapeutics during the second quarter worth $181,000. Susquehanna International Group LLP purchased a new position in Tvardi Therapeutics in the second quarter valued at about $63,000. Finally, GSA Capital Partners LLP purchased a new position in Tvardi Therapeutics in the second quarter valued at about $34,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.